Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Andrologia ; 48(4): 425-30, 2016 May.
Article in English | MEDLINE | ID: mdl-26268684

ABSTRACT

Post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND) represents an integral part of multidisciplinary treatment of advanced germ cell cancer; however, it is associated with a high complications rate. The present study aimed to describe sexual disorders in 53 patients with testicular cancer who underwent full bilateral, non-nerve-sparing PC-RPLND in our institution, focusing beyond ejaculatory dysfunction. The International Index for Erectile Function (IIEF) questionnaire was used as diagnostic tool of male sexual functioning pre-operatively and three months after RPLND, while post-operatively patients were asked to describe and evaluate changes in selected sexual parameters. Study findings demonstrate mixed pattern of changes in sexual functioning, with no difference in erectile functioning before and after operation. However, orgasmic function and intercourse and overall sexual satisfaction were found significantly impaired post-operatively. Sexual desire and frequency of attempted sexual intercourses were found significantly increased post-operatively, in comparison with pre-operative levels. With regard to patients' subjective perception on sexual functioning alterations after PC-RPLND, a significant number of patients reported higher levels of sexual desire, no difference in erectile function and worse orgasmic function and satisfaction post-operatively. Thus, patients subjected to PC-RPLND should be closely and routinely evaluated due to close relationship of sexual dissatisfaction with secondary psychological disorders.


Subject(s)
Ejaculation , Erectile Dysfunction/etiology , Lymph Node Excision/adverse effects , Neoplasms, Germ Cell and Embryonal/surgery , Testicular Neoplasms/surgery , Adult , Antineoplastic Agents/therapeutic use , Coitus/psychology , Combined Modality Therapy , Erectile Dysfunction/psychology , Greece , Humans , Lymph Node Excision/methods , Lymph Node Excision/psychology , Male , Neoplasms, Germ Cell and Embryonal/drug therapy , Orgasm , Prospective Studies , Retroperitoneal Space , Surveys and Questionnaires , Testicular Neoplasms/drug therapy , Young Adult
3.
Curr Mol Med ; 11(8): 623-32, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21902654

ABSTRACT

Approximately 70% to 80% of patients with urothelial carcinomas of the bladder are initially diagnosed with non-muscle invasive disease. Superficial, non-muscle invasive bladder cancers (NMIBCs) are managed with cystoscopic transurethral resection of all visible lesions followed by intravesical chemotherapy and/or immunotherapy. Despite this treatment, up to 70% of these tumors will recur within five years and 15% will ultimately progress to muscle-invasive disease, suggesting that novel therapeutic strategies are necessary. Recent studies have greatly advanced our understanding of urothelial carcinogenesis and have highlighted the distinct molecular pathogenesis of NMIBCs versus muscle-invasive bladder tumors. It is now clear that diverse genetic and epigenetic events are driving the oncogenesis of NMIBCs, thereby attesting to their potential as therapeutic targets for these tumors. This article reviews the molecular pathogenesis of NMIBCs, discusses recently completed and ongoing clinical trials and anticipates the future direction of molecular targeted agents in this disease.


Subject(s)
Carcinoma, Transitional Cell/drug therapy , Carcinoma, Transitional Cell/pathology , Signal Transduction , Urinary Bladder Neoplasms/drug therapy , Urinary Bladder Neoplasms/pathology , Animals , Carcinoma, Transitional Cell/genetics , Cell Transformation, Neoplastic/pathology , Gene Deletion , Humans , Receptor, Fibroblast Growth Factor, Type 3/metabolism , Urinary Bladder/pathology , Urinary Bladder Neoplasms/genetics
4.
J Med Case Rep ; 2: 144, 2008 May 05.
Article in English | MEDLINE | ID: mdl-18457585

ABSTRACT

INTRODUCTION: Congenital renal arteriovenous malformations (AVMs) are very rare benign lesions. They are more common in women and rarely manifest in elderly people. In some cases they present with massive hematuria. Contemporary treatment consists of transcatheter selective arterial embolization which leads to resolution of the hematuria whilst preserving renal parenchyma. CASE PRESENTATION: A 72-year-old man, who was heavy smoker, presented with massive hematuria and flank pain. CT scan revealed a filling defect caused by a soft tissue mass in the renal pelvis, which initially led to the suspicion of a transitional cell carcinoma (TCC) of the upper tract, in view of the patient's age and smoking habits. However a subsequent retrograde study could not depict any filling defect in the renal pelvis. Selective right renal arteriography confirmed the presence of a renal AVM by demonstrating abnormal arterial communication with a vein with early visualization of the venous system. At the same time successful selective transcatheter embolization of the lesion was performed. CONCLUSION: This case highlights the importance of careful diagnostic work-up in the evaluation of upper tract hematuria. In the case presented, a congenital renal AVM proved to be the cause of massive upper tract hematuria and flank pain in spite of the initial evidence indicating the likely diagnosis of a renal pelvis tumor.

SELECTION OF CITATIONS
SEARCH DETAIL
...